News items KWF 2 5 million Euros for cancer research
15 April 2021

The Radboudumc receives 2.56 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19. The projects that have been awarded focus on innovative research into ovarian cancer and groundbreaking immunotherapy.

Preventing Hereditary Ovarian Cancer - Joanne de Hullu

Women with an inherited error in the genes BRCA1 or BRCA2 have a greatly increased risk of ovarian cancer. They are advised to have their fallopian tubes and ovaries removed. This procedure is very effective, reducing the risk of ovarian cancer by 80-96%, but ovarian removal also leads to early menopause, with all its adverse consequences.
Joanne de Hullu, gynecologist, is investigating whether it is safe to remove the fallopian tubes (the presumed origin of ovarian cancer) first and only later the ovaries. The results of her previous KWF research show that this improves quality of life, especially in terms of menopausal symptoms and sexual functioning. 
In a large international study, Joanne de Hullu is now going to further map the risks. Together with nine other countries, she is investigating how often ovarian cancer occurs in women who opted for the new approach and what their quality of life is like. De Hullu hopes to show that the risk of ovarian cancer remains the same, but that patients experience a much better quality of life.

Improving immunotherapy - Harry Dolstra and Gosse Adema

There are also two studies that focus on immunotherapy. This research focuses on a groundbreaking treatment that helps the patient's immune system to clear cancer cells on its own. 
Harry Dolstra, associate professor at the Laboratory of Hematology, is working on immunotherapy for ovarian cancer using 'natural killer' cells. He is investigating the possibility of growing these types of immune cells in large quantities so that they can be injected directly, rather than small amounts for each patient individually. In addition, these "natural killer" cells are equipped with a CAR (chimeric antigen receptor), which serves as a kind of "grappler'' that enables them to better recognize and clear cancer cells. 

Gosse Adema professor of molecular immunology in the Radiotherapy & Oncoimmunology (ROI) laboratory of the Department of Radiotherapy, is researching sialic acids and their receptors. Sialic acids are sugars that cancer cells produce in increased amounts to protect themselves from attacks by the immune system. Gosse Adema is investigating whether the effect of immunotherapy can be improved by blocking these sialic acids or their receptors on immune cells.

The awards are part of the latest round of funding from KWF, in which more than 30 million Euros will be awarded to Dutch cancer research.

Related news items


KNAW Early Career Award for Martine Hoogman

2 December 2021

Martine Hoogman has been awarded a KNAW Early Career Award. The prize, a sum of 15,000 euros and a work of art, is aimed at researchers in the Netherlands who are at the start of their careers and have innovative, original research ideas.

read more

T-Guard can reset immune system

1 December 2021

For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard.

read more

Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI

1 December 2021

Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.

read more

Villa Joep Research Grant for Radiotherapy & OncoImmunology (ROI) lab

1 December 2021

Renske van den Bijgaart and Gosse Adema from the Radiotherapy & OncoImmunology laboratorium in collaboration with the Prinses Maxima Center received a grant from Villa Joep of 410k Euro.

read more

Participating in cancer research among people with intellectual disabilities

30 November 2021

Thanks to the support of the Maarten van der Weijden Foundation research was carried out into the participation of people with intellectual disabilities in (population) screening for cancer.

read more

Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more